Skip to main content

Table 4 Factors associated with 28-day mortality in patients with P. mirabilis bacteremia

From: The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea

Factors

Survivors N = 51 (%)

Nonsurvivors N = 11 (%)

p value

Age, y, median(IQR)

71.0 (63.0–79.0)

73.0 (54.0–84.0)

0.797

 Age ≥ 65 years, n(%)

32 (62.7)

7 (63.6)

1.000

Sex, male, n(%)

21 (41.2)

6 (54.6)

0.51

BMI, kg/m2, median(IQR)

22.35 (10.07–25.52)

21.78 (19.15–23.29)

0.366

ESBL producing pathogen, yes, n(%)

7 (13.7)

7 (63.6)

0.001

Infection source

 Urinary tract infection, n(%)

28 (54.9)

4 (36.4)

0.264

 Pneumonia, n(%)

6 (11.8)

3 (27.3)

0.191

 Skin and soft tissue infection, n(%)

2 (3.9)

0 (0)

1.000

 Biliary infection, n(%)

8 (15.7)

1 (9.1)

1.000

 Catheter related infection, n(%)

2 (3.9)

1 (9.1)

0.449

Comorbities

 HTN, n(%)

33 (64.7)

5 (45.5)

0.311

 DM, n(%)

21 (41.2)

3 (27.3)

0.505

 Cardiovascular disease, n(%)

5 (9.8)

3 (27.3)

0.142

 Chronic kidney disease, n(%)

7 (13.7)

0 (0)

0.334

 Chronic liver disease, n(%)

3 (5.9)

3 (27.3)

0.063

 Rheumatologic disease, n(%)

2 (3.9)

0 (0)

1.000

 Solid tumor, n(%)

26 (51.0)

6 (54.5)

0.83

 Hematologic malignancy, n(%)

1 (2.0)

1 (9.1)

0.326

 Solid organ transplantation, n(%)

2 (3.9)

1 (9.1)

0.449

 Charlson score, median(IQR)

2.0 (1.0–2.0)

2.0 (1.0–4.0)

0.239

Predisposing factors

 Neutropenia, n(%)

2 (4.0)

0 (0)

1.000

 Chemotherapy, n(%)

7 (13.7)

1 (9.1)

1.000

 Nursing home residence, n(%)

7 (13.7)

0 (0)

0.334

 Hemodialysis, n(%)

8 (15.7)

3 (27.3)

0.394

 Maintaining foley catheter, n(%)

11 (21.6)

6 (54.5)

0.056

 Maintaining PEG tube, n(%)

4 (7.8)

1 (9.1)

1.000

 ICU care, n(%)

13 (25.5)

6 (54.5)

0.077

 Previous antibiotic use, n(%)

13 (25.5)

7 (63.6)

0.029

  Cephalosporins, n(%)

6 (11.8)

2 (18.2)

0.623

  Carbapenems, n(%)

3 (5.9)

1 (9.1)

0.552

  Fluorquinolones, n(%)

1 (2.0)

2 (18.2)

0.079

  BLBLI, n(%)

3 (5.9)

2 (18.2)

0.212

Clinical presentation

 Shock, n(%)

19 (37.3)

4 (36.4)

1.000

 Acute kidney injury, n(%)

14 (27.5)

3 (27.3)

1.000

 APACHE II score, median(IQR)

11.0 (8.0–16.0)

17.0 (11.0–19.0)

0.027

 SOFA score, median(IQR)

2.0 (1.0–5.0)

5.0 (4.0–8.0)

0.033

 Inappropriate antimicrobial therapy, n(%)

10 (19.6)

5 (45.5)

0.115

  1. IQR interquartile range, BMI body mass index, ESBL extended spectrum β-lactamases, HTN hypertension, DM diabetes mellitus, PEG percutaneous endoscopic gastrostomy, ICU intensive care unit, BLBLIs beta-lactam/beta-lactamase inhibitors, APACHE II score Acute Physiology and Chronic Health Evaluation II score, SOFA score the Sequential Organ Failure Assessment score